December 1, 2022 – Renal & Urology News (By: Natasha Persaud) Veterans with cardiovascular disease or diabetes have slightly longer survival when treated with enzalutamide vs abiraterone for metastatic castration-resistant prostate cancer (mCRPC), a new study finds. In a retrospective study of 5822 veterans treated for mCRPC during 2014-2017, 43% initially received enzalutamide, an androgen…
Read More